148 related articles for article (PubMed ID: 36084863)
1. Use of high throughput ion channel profiling and statistical modeling to predict off-target arrhythmia risk - One pharma's experience and perspective.
Watt ED; Lee T; Feng SL; Kilfoil P; Ackley D; Keefer C; Wisialowski T; Jenkinson S
J Pharmacol Toxicol Methods; 2022; 118():107213. PubMed ID: 36084863
[TBL] [Abstract][Full Text] [Related]
2. Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk.
Mirams GR; Cui Y; Sher A; Fink M; Cooper J; Heath BM; McMahon NC; Gavaghan DJ; Noble D
Cardiovasc Res; 2011 Jul; 91(1):53-61. PubMed ID: 21300721
[TBL] [Abstract][Full Text] [Related]
3. MICE models: superior to the HERG model in predicting Torsade de Pointes.
Kramer J; Obejero-Paz CA; Myatt G; Kuryshev YA; Bruening-Wright A; Verducci JS; Brown AM
Sci Rep; 2013; 3():2100. PubMed ID: 23812503
[TBL] [Abstract][Full Text] [Related]
4. The atypic antipsychotic clozapine inhibits multiple cardiac ion channels.
Le Marois M; Sanson C; Maizières MA; Partiseti M; Bohme GA
Naunyn Schmiedebergs Arch Pharmacol; 2023 Jan; 396(1):161-166. PubMed ID: 36308551
[TBL] [Abstract][Full Text] [Related]
5. An evaluation of 30 clinical drugs against the comprehensive in vitro proarrhythmia assay (CiPA) proposed ion channel panel.
Crumb WJ; Vicente J; Johannesen L; Strauss DG
J Pharmacol Toxicol Methods; 2016; 81():251-62. PubMed ID: 27060526
[TBL] [Abstract][Full Text] [Related]
6. Comparative pharmacology of guinea pig cardiac myocyte and cloned hERG (I(Kr)) channel.
Davie C; Pierre-Valentin J; Pollard C; Standen N; Mitcheson J; Alexander P; Thong B
J Cardiovasc Electrophysiol; 2004 Nov; 15(11):1302-9. PubMed ID: 15574182
[TBL] [Abstract][Full Text] [Related]
7. A history of the role of the hERG channel in cardiac risk assessment.
Rampe D; Brown AM
J Pharmacol Toxicol Methods; 2013; 68(1):13-22. PubMed ID: 23538024
[TBL] [Abstract][Full Text] [Related]
8. Automated Patch-Clamp Methods for the hERG Cardiac Potassium Channel.
Houtmann S; Schombert B; Sanson C; Partiseti M; Bohme GA
Methods Mol Biol; 2017; 1641():187-199. PubMed ID: 28748465
[TBL] [Abstract][Full Text] [Related]
9. Development of models for predicting Torsade de Pointes cardiac arrhythmias using perceptron neural networks.
Sharifi M; Buzatu D; Harris S; Wilkes J
BMC Bioinformatics; 2017 Dec; 18(Suppl 14):497. PubMed ID: 29297274
[TBL] [Abstract][Full Text] [Related]
10. Revisiting the hERG safety margin after 20 years of routine hERG screening.
Leishman DJ; Abernathy MM; Wang EB
J Pharmacol Toxicol Methods; 2020 Sep; 105():106900. PubMed ID: 32768644
[TBL] [Abstract][Full Text] [Related]
11. The hERG potassium channel and hERG screening for drug-induced torsades de pointes.
Hancox JC; McPate MJ; El Harchi A; Zhang YH
Pharmacol Ther; 2008 Aug; 119(2):118-32. PubMed ID: 18616963
[TBL] [Abstract][Full Text] [Related]
12. QSAR modeling and data mining link Torsades de Pointes risk to the interplay of extent of metabolism, active transport, and HERG liability.
Broccatelli F; Mannhold R; Moriconi A; Giuli S; Carosati E
Mol Pharm; 2012 Aug; 9(8):2290-301. PubMed ID: 22742658
[TBL] [Abstract][Full Text] [Related]
13. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development.
Redfern WS; Carlsson L; Davis AS; Lynch WG; MacKenzie I; Palethorpe S; Siegl PK; Strang I; Sullivan AT; Wallis R; Camm AJ; Hammond TG
Cardiovasc Res; 2003 Apr; 58(1):32-45. PubMed ID: 12667944
[TBL] [Abstract][Full Text] [Related]
14. The [3H]dofetilide binding assay is a predictive screening tool for hERG blockade and proarrhythmia: Comparison of intact cell and membrane preparations and effects of altering [K+]o.
Diaz GJ; Daniell K; Leitza ST; Martin RL; Su Z; McDermott JS; Cox BF; Gintant GA
J Pharmacol Toxicol Methods; 2004; 50(3):187-99. PubMed ID: 15519905
[TBL] [Abstract][Full Text] [Related]
15. hERG inhibitors with similar potency but different binding kinetics do not pose the same proarrhythmic risk: implications for drug safety assessment.
DI Veroli GY; Davies MR; Zhang H; Abi-Gerges N; Boyett MR
J Cardiovasc Electrophysiol; 2014 Feb; 25(2):197-207. PubMed ID: 24118558
[TBL] [Abstract][Full Text] [Related]
16. Early evaluation of compound QT prolongation effects: a predictive 384-well fluorescence polarization binding assay for measuring hERG blockade.
Deacon M; Singleton D; Szalkai N; Pasieczny R; Peacock C; Price D; Boyd J; Boyd H; Steidl-Nichols JV; Williams C
J Pharmacol Toxicol Methods; 2007; 55(3):238-47. PubMed ID: 17141530
[TBL] [Abstract][Full Text] [Related]
17. Validation and Clinical Utility of the hERG IC50:C
Lehmann DF; Eggleston WD; Wang D
Pharmacotherapy; 2018 Mar; 38(3):341-348. PubMed ID: 29380488
[TBL] [Abstract][Full Text] [Related]
18. Improving the In Silico Assessment of Proarrhythmia Risk by Combining hERG (Human Ether-à-go-go-Related Gene) Channel-Drug Binding Kinetics and Multichannel Pharmacology.
Li Z; Dutta S; Sheng J; Tran PN; Wu W; Chang K; Mdluli T; Strauss DG; Colatsky T
Circ Arrhythm Electrophysiol; 2017 Feb; 10(2):e004628. PubMed ID: 28202629
[TBL] [Abstract][Full Text] [Related]
19. A mechanism for the proarrhythmic effects of cisapride (Propulsid): high affinity blockade of the human cardiac potassium channel HERG.
Rampe D; Roy ML; Dennis A; Brown AM
FEBS Lett; 1997 Nov; 417(1):28-32. PubMed ID: 9395068
[TBL] [Abstract][Full Text] [Related]
20. Arrhythmogenicity of Anti-Ro/SSA Antibodies in Patients With Torsades de Pointes.
Lazzerini PE; Yue Y; Srivastava U; Fabris F; Capecchi PL; Bertolozzi I; Bacarelli MR; Morozzi G; Acampa M; Natale M; El-Sherif N; Galeazzi M; Laghi-Pasini F; Boutjdir M
Circ Arrhythm Electrophysiol; 2016 Apr; 9(4):e003419. PubMed ID: 27030700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
